<?xml version="1.0" encoding="UTF-8"?>
<p>Emerging evidence suggests that activation of the complement system contributes to the pathogenesis of SARS-CoV-2 lung pathology (
 <xref rid="B136" ref-type="bibr">136</xref>, 
 <xref rid="B137" ref-type="bibr">137</xref>). Inhibition of the terminal complement pathway by targeting complement protein 5 (C5) has been proposed as an effective therapeutic intervention in CoV-mediated disease (
 <xref rid="B138" ref-type="bibr">138</xref>). Mannose-binding lectin (MBL) is a pattern recognition molecule, which binds to specific carbohydrate structures on the microbial surface, thereby activating complement terminal pathways (
 <xref rid="B139" ref-type="bibr">139</xref>). MBL serum immunodeficiency has been suggested to play a role, although controversial, in increased susceptibility to a wide range of viral and bacterial infections, mainly in children (
 <xref rid="B140" ref-type="bibr">140</xref>â€“
 <xref rid="B142" ref-type="bibr">142</xref>). A single study has identified that individuals carrying a low MBL-producing haplotype YB have an increased risk of acquiring SARS-CoV (
 <xref rid="B143" ref-type="bibr">143</xref>). Collectively, the precise role of the complement system as either having a detrimental or protective role in COVID-19 pathogenesis needs further study.
</p>
